Praxis Precision Medicines News and Activities
Presence
Praxis Precision Medicines develops therapies for central nervous system disorders. It provides precision medicine drug candidates and research services for patients, healthcare providers, and partners in biotechnology and pharmaceuticals.
Praxis Precision Medicines products and services overview:
- Neurology therapies
- Rare disease treatments
- Precision medicines
- Drug development
- Clinical research
Revenue: ~$4 million
Employees: 170
Headquarters: Boston, United States (USA)
Praxis Precision Medicines is one of the...
Praxis Precision Medicines is a company listed under the stock ticker PRAX (US).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at Praxis Precision Medicines
- Marcio Souza, President and Chief Executive Officer
- Jill Desimone, Director
- Merit Cudkowicz, Director
Popular executive movements at Praxis Precision Medicines
- Orrin Devinsky has joined the company as Head of Clinical Strategy (posted on January 14 2026).
- Megan Sniecinski, who was Chief Business Officer, is promoted to Chief Operating Officer (posted on January 9 2026).
- Steven Petrou, who was Chief Scientific Officer, is promoted to President of Research & Development (posted on January 9 2026).
Click here to view some more movements at Praxis Precision Medicines
Create your alert
to follow the executive moves at Praxis Precision Medicines.
Biotechnology
Praxis Precision Medicines has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Praxis Precision Medicines
- Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone - Praxis Precision Medicines, Inc.
- Press Releases | Praxis Precision Medicines, Inc.
- Praxis Precision Medicines to Present at Upcoming Investor Conferences - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines to Present at Upcoming Investor Conferences - Praxis Precision Medicines, Inc.
- Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients - Praxis Precision Medicines, Inc.
- View more press releases Close
Social media about Praxis Precision Medicines
- Praxis Precision Medicines on Wikipedia, Google News & Yahoo Finance
- Praxis Precision Medicines on LinkedIn, X (Twitter) & YouTube
